US Pharma MarketingAgios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
Source: FierceBiotech